In Depth: Chinese Drugmakers Find Fertile, but Challenging Market in Indonesia
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
The Indonesian-owned Etana factory, in the east of Jakarta, works with more than 10 Chinese companies such as CanSino, Sinovac, Watson, Aibo, and Cinda. Photo: Zhou Xinda
Indonesia, Southeast Asia’s largest economy, is turning into a critical entry point for Chinese drugmakers looking to expand overseas.
However, the archipelago nation has presented them with challenges, along with the opportunities.
Chinese drug producers have been under mounting pressure to find new sources of growth abroad as government measures to lower drug prices have squeezed profit margins. Indonesia presents possibilities.
You've accessed an article available only to subscribers
VIEW OPTIONS
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
Share this article
Open WeChat and scan the QR code
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新